[{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Incyte Corporation"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Imperial College London \/ Incyte Corporation"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Incyte Corporation"},{"orgOrder":0,"company":"University of Utah","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah \/ Incyte Corporation"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"||Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Douglas Johnson","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Douglas Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Douglas Johnson \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Douglas Johnson \/ Incyte Corporation"}]

Find Clinical Drug Pipeline Developments & Deals for Itacitinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 21, 2023

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 07, 2023

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Douglas Johnson

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Douglas Johnson

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hematologic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 21, 2022

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 30, 2022

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphohistiocytosis, Hemophagocytic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 30, 2021

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 23, 2020

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 16, 2020

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          University of Utah

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          University of Utah

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft vs Host Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 24, 2020

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 24, 2020

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Graft vs Host Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 07, 2020

                          Lead Product(s) : Itacitinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank